101 liver cancer drug candidates pave the way to personalized medicine

March 19, 2014
This is an illustration of the genome-scale metabolic models. Credit: Martina Butorac

The heart disease drug perhexiline is one of 101 compounds predicted to prevent cancer growth in most patients suffering from our most common liver cancer, HCC. This is an outcome from a novel simulation-based approach using personal sets of proteins of six HCC patients.

"This is the first time personalized models have been used to find and evaluate new potential drugs," says Professor Jens Nielsen at Chalmers University of Technology.

Our most common liver , Hepatocellular carcinoma, HCC, causes more than half a million deaths worldwide every year. If the cancer cannot be surgically removed the disease is usually deadly within 3-6 months. Only 30 percent of the patients respond to the best existing drug, sorenafib. This new research now identifies 101 drug candidates predicted to prevent the in all six studied patients, which raises hope of developing a drug helping all HCC-patients.

Cancer cells modify their metabolism in order to breed. To understand these diverse mechanisms, what metabolic enzymes are involved, when and how, has been a major focus in medicine in order to identify novel drug targets. However, this is quite a challenging task, since HCC not only involves a large number of interplays between different biological pathways, but also significant individual variations.

Finding the candidates

Average models don't give sufficiently good answers. To take the individual variations into account the researchers generated personalized proteomics data for HCC patients using the antibodies produced in the Human Protein Atlas project (read more below). The researchers then generated individual computer models for six HCC patients based on their entire, personal set of proteins and a generic map of human metabolism, which had been produced in an earlier project.

"I am excited to see how we have managed to successfully transfer our modelling approaches on yeast to study cancer metabolism," says Dr Rasmus Ågren, shared first author of the paper.

The six personal models were then used to find potential new anticancer drugs. One of the most common types of is so called antimetabolites. Antimetabolites prevent the use of one or more metabolites (the small molecules that act and are produced, and whose interplay together constitute a full metabolism) by stopping the catalyzing enzymes. By simulating the effect of all possible antimetabolites – more than 3000 compounds – the computer generated potential anti-cancer drugs which could be effective in inhibiting tumor growth.

Furthermore, the researchers simulated the effect of these antimetabolites on 83 major healthy cell types in human body to predict their toxic effects. This led to the identification of 101 antimetabolites which were predicted to prevent cancer growth in all six studied HCC patients, whereas 46 antimetabolites inhibited tumor growth only in one or a few of the patients. All 147 were predicted to not be overly toxic to healthy cells.

Clinical tests

The general validity of the approach can be extended by running personalized models for more patients.

"With this approach we can find and evaluate new potential drugs, some that could be used for general treatment of HCC, and others that are highly specific for each HCC patient. We can also predict false positive drug targets that would not be effective in all patients. This would lead to more targeted and efficient cancer treatment," says Dr Adil Mardinoglu, shared first author of the paper.

One of the antimetabolites was tested in vitro on a cell line. The tested compound, perhexiline, had an effect on viability comparable to sorafenib, demonstrating the predictive power of the computer models. Perhexiline is a drug approved for heart disease, and the potential to use it for HCC is of course interesting. As a continuation of this study, perhexiline will be tested on other cancer cell lines, since the researchers believe it may inhibit growth in other types of cancer as well. The initial experiments look very promising.

Read the article in Molecular Systems Biology: Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling

Mass production of personalized models with new algorithm

Tinit, a new algorithm for automatic reconstruction of personalized models, was recently developed at Chalmers University of Technology, branded as tINIT. Compared to previous algorithms it allows reconstruction of functional and simulation ready models. All the tools for have been made publically available in the so called Raven toolbox.

Proteomics data in Human Protein Atlas

All of the models were generated based on the generated in Human Protein Atlas, HPA. The Human Protein Atlas project is a world leading effort to systematically explore the human proteome in 46 different types of normal tissue and 216 different cancer tissues representing the 20 most common forms of human cancer. The atlas was recently used to generate a virtual map of , in a collaborative project between Chalmers University of Technology and researchers at SciLifeLab. This virtual map of human cell metabolism has the most comprehensive list of the entire set of known biochemical reactions which occurs in human body. The map contains more than 8,000 reactions and 3,765 associated genes, and it represents a great resource for systems biologists working in disorders related to metabolism.

Read the article in Molecular & Cellular Proteomics: Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics

Drug targets and biomarkers also for other liver conditions

The same type of modelling (however using an average model) has previously been used to investigate the most common liver disease, non-alcoholic fatty liver disease. This resulted in predictions of new drug targets, new biomarkers for diagnosis, as well as suggestions for dietary interventions.

Read more about that study in the Chalmers' news item Computer model takes us closer to treatment of our most common , or the Nature Communications article Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease.

Explore further: Research in fish provides new clues about deadly form of liver cancer

Related Stories

Research in fish provides new clues about deadly form of liver cancer

July 5, 2011
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is a leading cause of cancer-related deaths worldwide. Although there are several treatment options available, they are largely unsuccessful because the ...

Cardio could hold key to cancer cure

April 26, 2013
Regular exercise has been proven to reduce the chance of developing liver cancer in a world-first mice study that carries hope for patients at risk from hepatocellular carcinoma (HCC).

Kidney cancer reveals its weak link

February 18, 2014
A team of researchers at Chalmers University of Technology has found that kidney cancer cells have a quite different metabolism than other types of malignancies. The findings pave the way for new methods of diagnosing kidney ...

New compound discovered that rapidly kills liver cancer

March 14, 2012
Scientists have identified a new compound that rapidly kills hepatocellular carcinoma (HCC) cells, the most common form of liver cancer and fifth most common cancer worldwide, while sparing healthy tissue. The compound, Factor ...

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.